Bayer/Merck Cardio Rx Collaboration Pumped Up By Consumer Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck sells consumer care business, but also buys into Bayer’s franchise of sGC modulators.
You may also be interested in...
Merck/Bayer’s Vericiguat Outcomes Data Less Impressive On Fuller Disclosure
Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.
Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure
The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.